X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
Under the terms of the agreement, Searchlight will have sales and marketing rights for DONESTA® in Canada. DONESTA (estetrol) phase 3 clinical program, which demonstrated a meaningful reduction in the frequency and severity of vasomotor symptoms compared to placebo.
Lead Product(s): Estetrol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Donesta
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Mithra Pharmaceuticals
Deal Size: $17.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 26, 2023
Details:
Under the agreement, Searchlight will have the Canadian rights to Donesta, a next generation orally administered Estetrol (E4)-based hormone therapy product, for the treatment of the symptoms of menopause.
Lead Product(s): Estetrol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Donesta
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Mithra Pharmaceuticals
Deal Size: $18.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 31, 2023
Details:
Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of rosacea, in Canada.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sol-Gel Technologies
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
